F. De Chiara, K. Thomsen, A. Habtesion, H. Jones, N. Davies, J. Gracia‐Sancho, Nicolò Manicardi, A. Hall, F. Andreola, Hannah L. Paish, Lee H Reed, Abigail Watson, J. Leslie, F. Oakley, K. Rombouts, R. Mookerjee, J. Mann, R. Jalan
Hepatology, 2019
In nonalcoholic fatty liver disease (NAFLD), fibrosis is the most important factor contributing to NAFLD‐associated morbidity and mortality. Prevention of progression and reduction in fibrosis are the main aims of treatment. Even in early stages of NAFLD, hepatic and systemic hyperammonemia is evident. This is due to reduced urea synthesis; and as ammonia is known to activate hepatic stellate cells, we hypothesized that ammonia may be involved in the progression of fibrosis in NAFLD.
Cited by 19 publications.
Field of study: Medicine